Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. (AGIO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
agio · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Agios Pharmaceuticals, Inc. (AGIO) measures how much investors pay for each dollar of the company's trailing earnings. AGIO's current PE ratio of N/A is calculated by dividing its stock price of $27.93 by its TTM earnings per share of -$7.19.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Agios Pharmaceuticals, Inc.You AGIO | $1.7B | N/A | — | -$7.19 |
 Beam Therapeutics Inc. BEAM | $3.1B | N/A | — | -$0.81 |
 Cogent Biosciences, Inc. COGT | $5.4B | N/A | — | -$4.87 |
 Denali Therapeutics Inc. DNLI | $3.1B | N/A | — | -$2.92 |
 89bio, Inc. ETNB | $2.2B | N/A | — | -$3.51 |
 Galapagos N.V. GLPG | $1.8B | 5.74x | — | $4.85 |
 ImmunityBio, Inc. IBRX | $7.4B | N/A | — | -$0.38 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-7.12 | — | |
2024-12-31 FY2024 | 2.77x | $11.86 | — | |
2023-12-31 FY2023 | — | $-6.33 | — | |
2022-12-31 FY2022 | — | $-4.23 | — | |
2021-12-31 FY2021 | 1.24x | $26.55 | — | |
2020-12-31 FY2020 | — | $-4.74 | — | |
2019-12-31 FY2019 | — | $-6.86 | — | |
2018-12-31 FY2018 | — | $-6.03 | — | |
2017-12-31 FY2017 | — | $-6.75 | — | |
2016-12-31 FY2016 | — | $-5.07 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Agios Pharmaceuticals, Inc. (AGIO) measures how much investors pay for each dollar of the company's trailing earnings. AGIO's current PE ratio of N/A is calculated by dividing its stock price of $27.93 by its TTM earnings per share of -$7.19.
Frequently asked questions
AGIO pe ratio · 6 questionsAGIO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $27.93 and TTM EPS of -$7.19. Data sourced from Financial Modeling Prep via AGIO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Agios Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08